Intellia’s in vivo gene therapy victorious in Phase III HAE trial

Intellia’s CEO said that the trial marks the first positive Phase III readout for an in vivo CRISPR gene therapy.
Zacks Investment Research on MSN

NTLA falls 4% despite strong phase III HAE data, initiates rolling BLA

Shares of Intellia Therapeutics NTLA declined 4% on Monday despite positive top-line data from the global phase III HAELO ...
MPR

Gene Editing Candidate Lonvo-z Meets Endpoints in Phase 3 HAE Study

Lonvo-z is an in vivo CRISPR gene editing candidate that is designed to inactivate the kallikrein B1 gene, thereby permanently lowering kallikrein and bradykinin levels.
Hosted on MSN

Intellia's CRISPR therapy cuts HAE attacks 87% in phase 3

Intellia Therapeutics’ CRISPR-based therapy lonvoguran ziclumeran reduced hereditary angioedema attacks by 87% in a pivotal ...
MM&M

Ionis’ long-term HAE drug lowered attack rates, topline Phase 3 results show

Initial findings from a Phase 3 efficacy trial suggest Ionis Pharmaceuticals’ RNA-targeted treatment, given monthly or bimonthly, cut angioedema attacks more than placebo, the firm said Monday. The ...
Nasdaq

With HAE Drug EKTERLY Off To A Strong Start, Is Now The Time To Keep An Eye On KalVista Stock?

(RTTNews) - In July 2025, this pharmaceutical company started its new phase of growth as a commercial entity, following the landmark approval of the first and only oral on-demand treatment for ...